What Is Depression? Causes, Symptoms, Neuroscience, and Treatment

What Is Depression?

Depression — clinically known as Major Depressive Disorder (MDD) — is a prevalent and serious mental health condition characterized by persistent low mood, loss of interest or pleasure in activities, and a range of cognitive, physical, and behavioral symptoms that impair functioning. It is not a character flaw, weakness, or the same as ordinary sadness. Depression is a medical condition with identifiable neurobiological correlates and effective treatments.

Depression is one of the most common mental health conditions worldwide. According to the World Health Organization (WHO), approximately 280 million people globally live with depression — 5% of the world's adult population. It is a leading cause of disability and a major contributor to the global burden of disease. This article is for general educational purposes. If you or someone you know is experiencing depression, please consult a qualified mental health professional.

Depression vs. Sadness

Distinguishing clinical depression from normal sadness is important. Grief and sadness following loss, disappointment, or difficult life events are universal human experiences and do not constitute a disorder. Depression is distinguished by:

Duration: Symptoms must be present most of the day, nearly every day, for at least two weeks to meet diagnostic criteria.
Pervasiveness: The low mood is not limited to situations or events but colors virtually all experiences.
Anhedonia: Markedly diminished interest or pleasure in almost all activities — a hallmark feature distinct from sadness.
Functional impairment: Symptoms interfere significantly with work, relationships, or daily life.
Physical symptoms: Changes in sleep, appetite, energy, and psychomotor activity that are not characteristic of grief.

Diagnostic Criteria (DSM-5)

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) requires at least 5 of 9 symptoms present for at least 2 weeks, with at least one being depressed mood or anhedonia:

Depressed mood most of the day, nearly every day
Markedly diminished interest or pleasure in all or almost all activities (anhedonia)
Significant weight change (>5% in a month) or change in appetite
Insomnia or hypersomnia
Psychomotor agitation or retardation (observable by others)
Fatigue or loss of energy
Feelings of worthlessness or excessive/inappropriate guilt
Diminished ability to concentrate or make decisions
Recurrent thoughts of death or suicidal ideation

Causes and Risk Factors

Depression arises from a complex interaction of biological, psychological, and social factors — often summarized as the biopsychosocial model. No single cause explains all cases.

Biological Factors

Genetics: Depression has a heritability of approximately 37% based on twin studies. Having a first-degree relative with depression roughly doubles the risk. However, no single gene "causes" depression; risk arises from many common genetic variants.
Neurochemistry: The longstanding "serotonin deficiency hypothesis" — the idea that depression is caused by low serotonin — is an oversimplification. A 2022 umbrella review by Moncrieff et al. in Molecular Psychiatry found no consistent evidence of reduced serotonin activity in depression. Current models implicate dysregulation across multiple neurotransmitter systems (norepinephrine, dopamine, glutamate, GABA) and neuroinflammation rather than a single deficiency.
Neuroinflammation: Elevated inflammatory markers (cytokines, C-reactive protein) are found in a subset of depressed patients, particularly those with atypical features. Anti-inflammatory treatments are under investigation.
HPA axis dysregulation: The hypothalamic-pituitary-adrenal axis, which governs the stress response, is dysregulated in many people with depression, leading to elevated cortisol and impaired stress recovery.
Neuroplasticity and hippocampal volume: Depression is associated with reduced hippocampal volume and impaired neurogenesis. Effective antidepressant treatments (including both medication and exercise) increase BDNF (brain-derived neurotrophic factor), promoting synaptic plasticity and neurogenesis.

Psychological Factors

History of childhood trauma, abuse, or neglect
Negative cognitive styles — tendency toward negative self-attribution (Beck's cognitive model)
Learned helplessness — belief that one's actions cannot affect outcomes
Rumination — repetitive negative self-focused thinking

Social and Environmental Factors

Stressful life events (loss, divorce, financial crisis, job loss)
Social isolation and lack of social support
Chronic pain or medical illness
Substance abuse (both a risk factor and a consequence)

Depression Subtypes

Subtype	Key Feature
Major Depressive Disorder (MDD)	The primary diagnosis; single or recurrent episodes
Persistent Depressive Disorder (Dysthymia)	Lower severity but chronic (>2 years); often treatment-resistant
Seasonal Affective Disorder (SAD)	Recurrent episodes linked to reduced winter daylight; responds to light therapy
Postpartum Depression	Onset within 4 weeks of childbirth; affects approximately 10–15% of new mothers
Atypical Depression	Mood reactivity (brightens with positive events); hypersomnia, weight gain
Psychotic Depression	Accompanied by delusions or hallucinations; requires antipsychotic + antidepressant

Treatment

Depression has among the highest treatment success rates of any psychiatric condition. Major evidence-based treatments:

Psychotherapy

Cognitive Behavioral Therapy (CBT): The most extensively studied psychotherapy for depression. Targets negative thought patterns and maladaptive behaviors. Highly effective for mild to moderate depression; equivalent to antidepressants in many trials.
Behavioral Activation: Focuses on increasing engagement in rewarding activities; particularly effective for anhedonia.
Interpersonal Therapy (IPT): Focuses on interpersonal relationships and role transitions; equivalent efficacy to CBT in most trials.

Antidepressant Medications

SSRIs (Selective Serotonin Reuptake Inhibitors): Fluoxetine (Prozac), sertraline (Zoloft), escitalopram — first-line medications due to tolerability and safety.
SNRIs: Venlafaxine, duloxetine — effective; also help with comorbid anxiety and pain.
Bupropion: Norepinephrine-dopamine reuptake inhibitor; favorable side effect profile; particularly helpful for fatigue and concentration.
Tricyclics and MAOIs: Older classes; effective but broader side effect profiles; typically second or third-line.

Antidepressants are effective in approximately 40–60% of patients as first-line treatment. Treatment-resistant depression (failure to respond to 2+ adequate medication trials) affects approximately 30% of patients, prompting use of augmentation strategies, alternative medications, or neuromodulation.

Neuromodulation

Electroconvulsive Therapy (ECT): The most effective treatment for severe or treatment-resistant depression; response rates of 60–80%; used when rapid response is needed (active suicidality) or medications have failed.
Transcranial Magnetic Stimulation (TMS): Non-invasive; FDA-approved for MDD; effective for treatment-resistant cases with fewer side effects than ECT.
Ketamine/esketamine (Spravato): Rapid-acting; produces antidepressant effects within hours via NMDA glutamate receptor antagonism; FDA-approved for treatment-resistant depression.

Lifestyle

Exercise: Multiple meta-analyses show effects comparable to antidepressants for mild-to-moderate depression; 150 min/week of moderate aerobic exercise is the evidence-supported target.
Sleep: Sleep disturbance worsens depression and is both a symptom and a maintaining factor; cognitive behavioral therapy for insomnia (CBT-I) reduces depressive symptoms alongside improving sleep.
Social connection: Among the strongest protective factors; social isolation is a major risk factor.